RSV is the leading cause of lower respiratory tract infections in infants. Worldwide, acute lower respiratory infections associated with RSV account for about 1.4 million hospitalizations & 27,300 in-hospital deaths among infants under the age of 6 months annually, according to the WHO. Nirsevimab is a long-acting antibody given as a single intramuscular injection at a dose of 50 mg for infants with a body weight of less than 5 kg, and 100 mg for infants weighing at least 5 kg. If approved, nirsevimab will be the only preventative option for the broad newborn and infant population against RSV.